New hope for advanced tumors? first human trial of DS-3939a begins
NCT ID NCT05875168
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Asan Medical Center
WITHDRAWNSeoul, 05505, South Korea
-
Assistance Publique- de Marseille
RECRUITINGMarseille, 13005, France
-
Beijing Cancer Hospital
NOT_YET_RECRUITINGBeijing, 100142, China
-
Cancer Institute Hospital of Jfcr
RECRUITINGKōtoku, 135-8550, Japan
-
Centre Léon Bérard
RECRUITINGLyon, 69008, France
-
Chu Strasbourg
RECRUITINGStrasbourg, 67091, France
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
Hospital Regional Universitario de Malaga
RECRUITINGMálaga, 29010, Spain
-
Hospital Universitari Vall D'Hebron
RECRUITINGBarcelona, 8035, Spain
-
Hospital Universitario La Paz
RECRUITINGMadrid, 28046, Spain
-
Hospital Universitario Ramon Y Cajal
RECRUITINGMadrid, 28034, Spain
-
Hospital Universitario Virgen Macarena
RECRUITINGSeville, 41009, Spain
-
Huntsman Cancer Institute, University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Institut Claudius Regaud
RECRUITINGToulouse, 31059, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Kansai Medical University Hospital
RECRUITINGHirakata-shi, 573-1191, Japan
-
Kindai University Hospital
RECRUITINGŌsaka-sayama, 589-8511, Japan
-
McGill University Health Center
NOT_YET_RECRUITINGMontreal, H4A 3J1, Canada
-
National Cancer Center Hospital
RECRUITINGChūōku, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, 277-8577, Japan
-
Next Madrid
RECRUITINGPozuelo de Alarcón, 28223, Spain
-
Oregon Health & Science University
RECRUITINGPortland, Oregon, 97239, United States
-
Osaka International Cancer Institute
RECRUITINGOsaka, 541-8567, Japan
-
Princess Margaret Cancer Center
ACTIVE_NOT_RECRUITINGToronto, M5G2M9, Canada
-
Rhode Island Hospital
RECRUITINGProvidence, Rhode Island, 02903, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Sendai Kousei Hospital
RECRUITINGSendai, 981-0914, Japan
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
-
Shandong Cancer Hospital
RECRUITINGJinan, 250117, China
-
Shanghai East Hospital
RECRUITINGShanghai, 200120, China
-
The Medical College of Wisconsin, INC
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
The Second Peoples Hospital of Neijiang
RECRUITINGNeijiang, 641000, China
-
UZ Leuven
RECRUITINGLeuven, 3000, Belgium
-
University of Kansas Medical Center
RECRUITINGWestwood, Kansas, 66205, United States
-
University of Texas M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?